

## ICMJE DISCLOSURE FORM

**Date:** 9 May 2022

**Your Name:** Laura C. Coates

**Manuscript Title:** Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study

**Manuscript number (if known):** ar-22-0051.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	UCB Pharma	
		Costello Medical	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AbbVie	
		Amgen	
		Celgene	
		Eli Lilly	
		Janssen	
		Novartis	
		Pfizer	
	UCB Pharma		

3	Royalties or licenses	___ None	
4	Consulting fees	AbbVie	
		Amgen	
		Boehringer Ingelheim	
		BMS	
		Celgene	
		Eli Lilly	
		Gilead	
		Galapagos	
		Janssen	
		Novartis	
		Pfizer	
UCB Pharma			
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AbbVie	
		Amgen	
		Biogen	
		Celgene	
		Eli Lilly	
		Galapagos	
		Gilead	
		Janssen	
		Medac	
		Novartis	
		Pfizer	
UCB Pharma			
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical	___ None	

	writing, gifts or other services		
13	Other financial or non-financial interests	<u>    </u> None	

Please place an "X" next to the following statement to indicate your agreement:

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

**Date:** 9 May 2022

**Your Name:** Iain B. McInnes

**Manuscript Title:** Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study

**Manuscript number (if known):** ar-22-0051.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	UCB Pharma	
		Costello Medical	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	BMS	
		Boehringer Ingelheim	
		Celgene	
		GSK	
		Eli Lilly	
		Janssen	
		Novartis	
	UCB Pharma		

3	Royalties or licenses	___ None	
4	Consulting fees	AbbVie	
		AstraZeneca	
		Boehringer Ingelheim	
		BMS	
		Celgene	
		Eli Lilly	
		Evelo	
		Janssen	
		Novartis	
		Pfizer	
		Sanofi-Regeneron	
		UCB Pharma	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AbbVie	
		AstraZeneca	
		Boehringer Ingelheim	
		BMS	
		Celgene	
		Eli Lilly	
		Evelo	
		Janssen	
		Novartis	
		Pfizer	
		Sanofi-Regeneron	
		UCB Pharma	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12		___ None	

	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	<u>    </u> None	

Please place an "X" next to the following statement to indicate your agreement:

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.



3	Royalties or licenses	___ None	
4	Consulting fees	AbbVie	
		Amgen	
		Bayer	
		Biogen	
		BMS	
		Celgene	
		Eli Lilly	
		Janssen	
		Novartis	
		Pfizer	
		Sanofi-Regeneron	
		UCB Pharma	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12		___ None	



	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	Dermavant LEO Pharma UCB Pharma	Principal investigator

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

**Date:** 9 May 2022

**Your Name:** Richard B. Warren

**Manuscript Title:** Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study

**Manuscript number (if known):** ar-22-0051.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	UCB Pharma	
		Costello Medical	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AbbVie	Grants to his institution
		Almirall	
		Janssen	
		LEO Pharma	
		Novartis	
		UCB Pharma	

3	Royalties or licenses	___ None	
4	Consulting fees	AbbVie	
		Almirall	
		Amgen	
		Arena	
		Astellas	
		Avillion	
		BMS	
		Boehringer Ingelheim	
		Celgene	
		Eli Lilly	
		GSK	
		Janssen	
		LEO Pharma	
		Novartis	
		Pfizer	
		Sanofi	
		UCB Pharma	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society,	___ None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<u>    </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>    </u> None	
13	Other financial or non-financial interests	Dermavant LEO Pharma UCB Pharma	Principal investigator

Please place an "X" next to the following statement to indicate your agreement:

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this Form.

## ICMJE DISCLOSURE FORM

**Date:** 9 May 2022

**Your Name:** Arthur Kavanaugh

**Manuscript Title:** Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study

**Manuscript number (if known):** ar-22-0051.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	UCB Pharma	
		Costello Medical	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Abbott	
		Amgen	
		BMS	
		Pfizer	
		Roche	
		Janssen	
		UCB Pharma	

3	Royalties or licenses	___ None	
4	Consulting fees	_ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12		___ None	

	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	<u>    </u> None	

Please place an "X" next to the following statement to indicate your agreement:

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

**Date:** 9 May 2022

**Your Name:** Alice B. Gottlieb

**Manuscript Title:** Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study

**Manuscript number (if known):** ar-22-0051.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	UCB Pharma	
		Costello Medical	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Boehringer Ingelheim	Paid to Mount Sinai Medical School
		Incyte	
		Janssen	
		Novartis	
		Sun Pharma	
		UCB Pharma	
		XBiotech	



3	Royalties or licenses	___ None	
4	Consulting fees	Anaptyps Bio	
		Avotres Therapeutics	
		Beiersdorf	
		BMS	
		Boehringer Ingelheim	
		Eli Lilly	
		Incyte	
		Janssen	
		LEO Pharma	
		Novartis	
		Pfizer	
		Sun Pharma	
		UCB Pharma	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Anaptyps Bio	
		Avotres Therapeutics	
		Beiersdorf	
		BMS	
		Boehringer Ingelheim	
		Eli Lilly	
		Incyte	
		Janssen	
		LEO Pharma	
		Novartis	
		Pfizer	
		Sun Pharma	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	XBiotech	

12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>    </u> None	
13	Other financial or non-financial interests	<u>    </u> None	

Please place an "X" next to the following statement to indicate your agreement:

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

**Date:** 9 May 2022

**Your Name:** Laure Gossec

**Manuscript Title:** Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study

**Manuscript number (if known):** ar-22-0051.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	UCB Pharma	
		Costello Medical	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Amgen	
		Galapagos	
		Eli Lilly	
		Pfizer	
		Sandoz	
		Sanofi	

3	Royalties or licenses	___ None	
4	Consulting fees	AbbVie	
		Amgen	
		BMS	
		Biogen	
		Celgene	
		Eli Lilly	
		Galapagos	
		Gilead	
		Janssen	
		Novartis	
		Pfizer	
		Samsung Bioepis	
		Sanofi-Aventis	
		UCB Pharma	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	

12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>    </u> None	
13	Other financial or non-financial interests	<u>    </u> None	

Please place an "X" next to the following statement to indicate your agreement:

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.



3	Royalties or licenses	___ None	
4	Consulting fees	_ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	UCB Pharma	
12		___ None	

	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	UCB Pharma	Employee

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.





3	Royalties or licenses	___ None	
4	Consulting fees	_ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	UCB Pharma	
12		___ None	

	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	UCB Pharma	Employee

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.



3	Royalties or licenses	___ None	
4	Consulting fees	_ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	UCB Pharma	
12		___ None	

	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	UCB Pharma	Employee

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.



3	Royalties or licenses	___ None	
4	Consulting fees	_ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	UCB Pharma GSK	
12		___ None	



	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	UCB Pharma	Employee

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

**Date:** 9 May 2022

**Your Name:** Christopher T. Ritchlin

**Manuscript Title:** Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study

**Manuscript number (if known):** ar-22-0051.R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	UCB Pharma	
		Costello Medical	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AbbVie	
		Amgen	
		UCB Pharma	

3	Royalties or licenses	___ None	
4	Consulting fees	AbbVie	
		Amgen	
		Eli Lilly	
		Gilead	
		Janssen	
		Novartis	
		Pfizer	
		UCB Pharma	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	_ None	
12		___ None	

	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests	<u>None</u>	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.